SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunoGen
IMGN 31.230.0%Feb 26 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JamesK who wrote (5597)3/27/2018 6:50:32 PM
From: Gary Mohilner   of 5665
 
I realize the Phase 2 would have to be expanded to consider an approval, but that's a possibility.

I learned what brought the stock down dramatically today, Charles Schwab. They determined that due to IMGN's volatility, they were making IMGN non-marginable as of last Friday, and people with margin in their Schwab accounts were suddenly hit with major margin calls. I spoke to a broker their and stated that in my opinion it was market manipulation by Schwab, his defense was they warn their investors of the risk with using margin. This IMHO was a risk that no investor could anticipate.

I've not used margin for decades, but I remember being pressed when margin requirement changed, but nothing this drastic. In that case, a stock that was fully marginable was reduced in the percentage that it could be margined, if I remember correctly, they brought it down by 20%.

I could understand a brokerage lowering the margin for a stock that's making new highs every week, but taking it instantaneously down to zero clearly would bring the stock down, which it did. I don't know if the selling is yet over.

Gary
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext